Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Drops By 6.3%

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 14,240,000 shares, a decline of 6.3% from the October 31st total of 15,200,000 shares. Based on an average daily volume of 5,080,000 shares, the days-to-cover ratio is presently 2.8 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

Institutional Trading of ADMA Biologics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp grew its position in shares of ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the period. Bank of Montreal Can bought a new position in ADMA Biologics during the second quarter worth about $17,886,000. D. E. Shaw & Co. Inc. grew its holdings in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the period. Principal Financial Group Inc. increased its position in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares during the last quarter. Finally, First Turn Management LLC bought a new stake in ADMA Biologics in the third quarter valued at approximately $13,293,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.69 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a 50-day moving average of $19.07 and a 200-day moving average of $15.47. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 70.32 and a beta of 0.64. ADMA Biologics has a fifty-two week low of $3.60 and a fifty-two week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period last year, the company earned $0.01 earnings per share. As a group, sell-side analysts predict that ADMA Biologics will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.